Reata Pharmaceuticals

Reata Pharmaceuticals, Inc.
Nasdaq: RETA
IndustryBiotechnology
Founded1 January 2002 Edit this on Wikidata
FateAcquired by Biogen
RevenueDecrease US $26.52 million (2019)
Increase US $53.59 million (2018)[1]
Owner
Websitewww.reatapharma.com

Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[3]

In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion.[4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.[5]

  1. ^ "RETA | Reata Pharmaceuticals Inc. Cl a Annual Income Statement".
  2. ^ "Our Story". Reata Pharmaceuticals. Retrieved 5 August 2016.
  3. ^ Sporn MB, Liby KT, Yore MM, et al. (2011). "New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress". J Nat Prod. 74 (3): 537–45. doi:10.1021/np100826q. PMC 3064114. PMID 21309592.
  4. ^ Mishra, Manas; Satija, Bhanvi; Satija, Bhanvi (2023-07-28). "Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio". Reuters. Retrieved 2023-07-28.
  5. ^ "Biogen Completes Acquisition of Reata Pharmaceuticals". Yahoo! Finance. 26 September 2023. Retrieved 2023-10-05.